AchievementsWhat sets Bristol-Myers Squibb apart? It's our commitment to patients with serious diseases, and our focus on finding innovative medicines to combat those diseases.
Over the years, Bristol-Myers Squibb and its employees have received numerous distinguished awards and recognitions, including the National Medal of Technology, the Lasker Award for Medical Research and the Prix Galien Award. Also, we've been hailed year after year as one of the best companies for working mothers, a great place to work for scientists and an acknowledged industry leader in environment, health and safety.
Below is a selection of awards and recognitions we have received.
Bristol-Myers Squibb received the 2015 Collaborator Award from the Multiple Myeloma Research Foundation (MMRF) in recognition of the company’s commitment to collaboration and to advancing the research and development of novel therapies for patients with multiple myeloma. The Collaborator Award is part of an annual initiative by the MMRF to recognize the exceptional work of its partners from industry and academia who have played a critical role toward pursuing innovative means in the development of next-generation multiple myeloma treatments. Watch the video.
Bristol-Myers Squibb has been honored with the 2015 Society for Immunotherapy of Cancer (SITC) Collaborator Award (Industry) for demonstrating ongoing collaboration and continued commitment toward the advancement of cancer immunotherapy. The award was part of SITC’s 30th Anniversary Awards, which were created to highlight groups and individuals who stand out as advocates for the society, and whose involvement in the organization has strengthened its position in the growing field of cancer immunotherapy.
In October, Bristol-Myers Squibb was recognized by Science Careers as a 2015 Top 20 R&D Employer. Our company was lauded for being an “Innovating leader in the industry” and commended for the respect afforded our employees and the loyalty they show return. Science also noted our willingness to take risks that are backed by good science and our leading position in Immuno-Oncology. Overall, Science found that Bristol-Myers Squibb is an exciting place to work.
Bristol-Myers Squibb’s Opdivo received the Prix Galien USA 2015 Award for Best Biotechnology Product. This represents the second award from Prix Galien USA given to Bristol-Myers Squibb’s Immuno-Oncology portfolio. Yervoy was awarded the prestigious Prix Galien USA prize for Best Biotechnology Product in 2012.
Bristol-Myers Squibb is recognized as one of Dow Jones’ 2015 North America Index of Leading Sustainable Companies. Our efforts to promote economic, social and environmental sustainability are core to our company’s mission and reflect our ongoing commitment to patients, our employees and partners, the environment, and communities around the world.
In June, the MIT Technology Review named Bristol-Myers Squibb to its 50 Smartest Companies list for 2015. Bristol-Myers Squibb was ranked No. 26, and recognized as a leader in Immuno-Oncology.
For the seventh consecutive year, Bristol-Myers Squibb ranks among the top 10 on Corporate Responsibility magazine’s list of the 100 Best Corporate Citizens. The company ranked sixth this year and has achieved the #1 ranking three times – in 2009, 2012 and 2014.
Bristol-Myers Squibb was ranked No. 4 among the World’s Most Admired Companies in the pharmaceutical industry, according to the 2015 annual ranking published by FORTUNE magazine. Bristol-Myers Squibb ranked in the top three pharmaceutical companies for innovation and social responsibility.
For the ninth consecutive year, Bristol-Myers Squibb received a perfect score of 100 percent on the 2015 Corporate Equality Index (CEI), a national review of workplace equality conducted annually by the Human Rights Campaign Foundation, the nation’s largest lesbian, gay, bisexual and transgender (LGBT) civil rights organization.
In December, Bristol-Myers Squibb was named one of the 10 Best of Green Schools award winners selected by the U.S. Green Building Council’s (USGBC) Center for Green Schools. The award recognizes 10 individuals, institutions, projects or events identified as national leaders and innovators in school sustainability. Bristol-Myers Squibb is being recognized in the Business Leadership category.
Bristol-Myers Squibb is recognized as one of the 2014 Working Mother 100 Best Companies – marking the 17th consecutive year that our company has made the list. The company was recognized for outstanding leadership in establishing policies, programs and a corporate culture that supports working moms.
Bristol-Myers Squibb researchers received a 2014 PhRMA Research and Hope Award for Biopharmaceutical Industry Research. A interdisciplinary team of five Bristol-Myers Squibb researchers were recognized for the discovery and development of a new HIV treatment.
The Philadelphia Veterans Administration Medical Center (PVAMC) recognizes Bristol-Myers Squibb with a 2014 Community Partner Award. The award is a prestigious honor presented each year by the PVAMC to recognize those companies and organizations that have been instrumental in embracing the Veterans Administration (VA) mission and to acknowledge company employees who volunteer in support of U.S. Military veterans.
A Bristol-Myers Squibb employee is named one of the 13 winners of a 2014 We Work for Health Champions Award given by the Pharmaceutical Research and Manufacturers of America (PhRMA). The award honors industry employees who have gone “above and beyond” their day jobs to give back to their communities and serve as advocates for the biopharmaceutical industry.
Bristol-Myers Squibb is named one of the 2014 Top 50 Companies for Executive Women by the National Association for Female Executives (NAFE). The recognition honors American corporations that identify and promote successful women. This is the 12th year in a row that we have received the award.
A Forbes’ science reporter ranked Bristol-Myers Squibb first in a year-end ranking of top pharmaceutical companies. Bristol-Myers Squibb scored an A+ in a summary of the 16 major pharmaceutical companies (as defined by a market capitalization of greater than $50 billion). The rankings were based on stock performance, scientific and medical output and company ethics.